{
    "clinical_study": {
        "@rank": "96035", 
        "brief_summary": {
            "textblock": "To determine safety and efficacy of ACH-126,443 on the treatment of adults with HIV\n      infection who have modestly detectable viral load while on stable triple combination\n      antiretroviral therapy including 3TC."
        }, 
        "brief_title": "Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.", 
        "completion_date": {
            "#text": "May 2003", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults \u226518 years of age\n\n          -  Receiving a stable triple combination antiretroviral regimen including 3TC, one other\n             NRTI and either an NNRTI or a protease inhibitor for at least 4 months (16 weeks)\n\n          -  Demonstration of initial viral suppression and subsequent rebound to be defined as an\n             initial virological drop of at least 0.5 Logs on a 3TC-containing regimen\n\n          -  Plasma HIV RNA level > 1000 and < 30,000 copies/mL on two occasions\n\n          -  Genotypically documented M184V variant of HIV RT\n\n          -  Clinically stable HIV status with no AIDS-defining events\n\n          -  CD4 > 200 cells/mm3\n\n          -  Basic hematologic and chemistry parameters within acceptable limits (defined in\n             protocol)\n\n          -  All women of child bearing potential must have a negative serum or urine pregnancy\n             test (minimum sensitivity of 25 IU/L of b-HCG) within 72 hours prior to the start of\n             study medication\n\n          -  No active opportunistic infection requiring treatment\n\n          -  Subject must be able to provide written informed consent\n\n          -  Baseline laboratory values measured within 28 days of initiating study drug as\n             follows:\n\n          -  HGB\u22659.0g/dl or HCT\u226527% (in the absence of blood transfusions or erythropoietin\n             treatment in the preceding two weeks\n\n          -  Absolute neutrophil count\u22651000 cells/mm(^3) (in the absence of on-going G-CSF therapy\n\n          -  Platelet count \u226575,000/mm(^3)\n\n          -  AST <7.0 times the upper limit of normal\n\n          -  ALT ,7.0 times the upper limit of normal\n\n          -  Serum creatinine <1.1 times the upper limit of normal\n\n        Exclusion Criteria\n\n          -  Evidence of active HBV infection as demonstrated by HBsAg positivity\n\n          -  Hepatitis C co-infection\n\n          -  Concurrent systemic antiviral treatment\n\n          -  Previous therapy with agents with significant systemic myelosuppressive or cytotoxic\n             potential within 3 months of study start or the expected need for such therapy at\n             study start.\n\n          -  Alcohol abuse\n\n          -  Pregnancy or breast-feeding\n\n          -  Inability to tolerate oral medication\n\n          -  AST > 7.0 times the upper limit of normal\n\n          -  ALT > 7.0 times the upper limit of normal\n\n          -  Any clinical condition or prior therapy that, in the Investigators opinion, would\n             make the subject unsuitable for the study or unable to comply with the dosing\n             requirements.\n\n          -  Use of any other drug or substance with anti-HBV activity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "June 21, 2002", 
        "id_info": {
            "nct_id": "NCT00040157", 
            "org_study_id": "ACH443-006"
        }, 
        "intervention": {
            "intervention_name": "ACH126-443 (Beta-L-Fd4C)", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "treatment experienced,", 
            "Stable triple anti-retroviral combination therapy in HIV-infected,", 
            "Achillion"
        ], 
        "lastchanged_date": "August 18, 2009", 
        "link": {
            "url": "http://www.achillion.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85006"
                    }, 
                    "name": "Body Positive, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "L.a.", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Pacific Horizon Medical Group, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ft. Lauderdale", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33306"
                    }, 
                    "name": "Community Health Care Center One, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33160"
                    }, 
                    "name": "South Shore Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "AIDS Research Consortium"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10019"
                    }, 
                    "name": "St. Lukes Roosevelt Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stony Brook", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11794-8153"
                    }, 
                    "name": "Stony Brook University Infectious Disease, Dept. of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77098"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hampton", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23666"
                    }, 
                    "name": "Hampton Road Medical Specialists"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98122"
                    }, 
                    "name": "Swedish Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase 2 Trial of 4 Weeks of ACH-126,443 in Comparison With Continued Lamivudine in Stable Triple Antiretroviral Combination Therapy in HIV-Infected Subjects With Modestly Detectable Viral Load", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040157"
        }, 
        "source": "Achillion Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Achillion Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2009", 
        "why_stopped": "Safety concerns"
    }, 
    "geocoordinates": {
        "null": "29.76 -95.369", 
        "AIDS Research Consortium": "33.749 -84.388", 
        "Body Positive, Inc.": "33.448 -112.074", 
        "Community Health Care Center One, Inc.": "26.122 -80.143", 
        "Hampton Road Medical Specialists": "37.03 -76.345", 
        "Pacific Horizon Medical Group, Inc.": "37.775 -122.419", 
        "South Shore Hospital": "25.791 -80.13", 
        "St. Lukes Roosevelt Hospital": "40.714 -74.006", 
        "Stony Brook University Infectious Disease, Dept. of Medicine": "40.926 -73.141", 
        "Swedish Medical Center": "47.606 -122.332"
    }
}